Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 6/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | COMT | P21964 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177157 | 0.81 | CYP2A6 (0.52) | HPGDMETKAT2BIKBKBCHUK | |
| SCHEMBL19225673 | 0.81 | MET (0.38) | HPGDMETALDH1A1KAT2BLIMK1 | |
| SCHEMBL25030039 | 0.78 | HTR2A (0.41) | MET | |
| SCHEMBL25029588 | 0.78 | HTR2A (0.40) | HPGDMETALDH1A1POLB | |
| SCHEMBL25030279 | 0.76 | HTR2A (0.46) | HPGDMETALDH1A1KAT2BPOLB | |
| SCHEMBL25030209 | 0.75 | CHRNB2 (0.38) | METHSP90AA1 | |
| SCHEMBL12334 | 0.75 | NPC1 (0.43) | KAT2BLIMK1NPC1HSP90AA1L3MBTL1 | |
| SCHEMBL25030128 | 0.74 | HTR2A (0.39) | MET | |
| SCHEMBL10280663 | 0.73 | LMNA (0.42) | HPGDMETALDH1A1LIMK1POLB | |
| SCHEMBL25029551 | 0.73 | HTT (0.36) | HPGDMETALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580430-B2 | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-02-28 | — | — | US | disclosed |
| US-8987269-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-03-24 | — | — | US | disclosed |
| US-20120264739-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264739-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | KCNJ11, NISCH, CYP4Z1 | HPGD 328/4885MET 4578/4885ALDH1A1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.